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ABSTRACT 40 
Incretin therapies have received significant attention because of their tissue-protective 41 
effects, which extend beyond those associated with glycemic control. Cancer is a 42 
primary cause of death in patients with diabetes mellitus. We previously reported 43 
anti-prostate cancer effects of the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) 44 
agonist exendin-4 (Ex-4). Breast cancer is one of the most common cancers in female 45 
patients with type 2 diabetes mellitus and obesity. Thus, we examined whether GLP-1 46 
action could attenuate breast cancer. GLP-1R was expressed in human breast cancer 47 
tissue and MCF-7, MDA-MB-231 and KPL-1 cell lines. We found that 0.1–10 nM Ex-4 48 
significantly decreased the number of breast cancer cells in a dose-dependent manner. 49 
Although Ex-4 did not induce apoptosis, it attenuated breast cancer cell proliferation 50 
significantly and dose-dependently. However, the dipeptidyl peptidase-4 inhibitor 51 
linagliptin did not affect breast cancer cell proliferation. When MCF-7 cells were 52 
transplanted into athymic mice, Ex-4 decreased MCF-7 tumor size in vivo. Ki67 53 
immunohistochemistry revealed that breast cancer cell proliferation was significantly 54 
reduced in tumors extracted from Ex-4-treated mice. In MCF-7 cells, Ex-4 significantly 55 
inhibited nuclear factor-κB nuclear translocation and target gene expression. 56 
Furthermore, Ex-4 decreased both Akt and IκB phosphorylation. These results suggest 57 
that GLP-1 could attenuate breast cancer cell proliferation via activation of GLP-1R and 58 
subsequent inhibition of nuclear factor-κB activation. 59 
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INTRODUCTION 76 
Incretin therapies, which include dipeptidyl peptidase-4 inhibitors and 77 
glucagon-like peptide-1 receptor (GLP-1R) agonists, have become popular treatments 78 
for type 2 diabetes mellitus (T2DM). Recently, incretin therapies have garnered 79 
significant attention because of their reported tissue-protective effects, which go beyond 80 
the benefits associated with reducing blood glucose (1). Patients with diabetes mellitus 81 
have a higher risk of cardiovascular events than individuals without diabetes mellitus 82 
(2) and frequently experience restenosis after coronary angioplasty, even if intervention 83 
was performed with currently established drug-eluting stents (3). Accordingly, the 84 
potential of incretin-related anti-diabetic agents to benefit not only glycemic control but 85 
also the cardiovascular system has been investigated. We previously demonstrated 86 
vascular-protective effects of exendin-4 (Ex-4), a GLP-1R agonist, which included 87 
attenuation of atheroma formation in apoE−/− mice (4) and reduction in intimal 88 
thickening after vascular injury (5). Thus, incretin therapies could improve quality of 89 
life and reduce mortality rates among patients with diabetes via vascular-protective 90 
effects. 91 
 Cancer is emerging as a major cause of death in patients with diabetes mellitus 92 
(6). Notably, in Japan, cancer is the leading cause of death in patients with T2DM (7). 93 
The Japan Diabetes Society and Japan Cancer Association have therefore issued a 94 
warning regarding increased cancer risk in patients with diabetes (8). Furthermore, a 95 
study by Hirakawa et al. suggested that not only diabetes, but also impaired glucose 96 
tolerance, increases the incidence of cancer-related deaths in the Japanese population (9). 97 
Specifically, diabetes and metabolic syndrome have been suggested to be associated 98 
with a higher risk of many cancers (10). 99 
 We previously demonstrated anti-prostate cancer effects of Ex-4 that occurred 100 
via inhibition of ERK-MAPK phosphorylation both in vivo and in vitro (11). 101 
Additionally, we observed a further reduction in tumor size and prostate cancer cell 102 
proliferation with combined Ex-4 and metformin therapy (12), independent of the 103 
glucose-lowering effect of this treatment. Although several reports have examined the 104 
effect of GLP-1 action on several types of cancers (13), the precise effect and 105 
mechanism of GLP-1 action on breast cancer remain unclear. Breast cancer is a major 106 
cancer in women, especially in western countries, and is accelerated in female patients 107 
with diabetes mellitus. It has been reported that women with T2DM have a 1.2-fold 108 
higher risk of breast cancer than women without T2DM (14). In the present study, we 109 
examined the anti-cancer effect of the anti-diabetic GLP-1R agonist Ex-4, using a breast 110 
cancer model. We revealed that Ex-4 attenuated breast cancer growth by inhibiting 111 
nuclear factor-κB (NF-κB) activation. Thus, Ex-4 has benefits in addition to its 112 
glucose-lowering effect. 113 
MATERIALS AND METHODS 114 
Human tissues 115 
Human breast cancer tissues were obtained from three non-diabetic patients with breast 116 
cancer (one aged 34 years and two aged 57 years) after mammary gland resection at 117 
Fukuoka University Hospital. The tissues were paraffin-embedded, formalin-fixed and 118 
cut into 3-µm sections for immunofluorescence staining. Two sections were cut and 119 
stained from each of three independent breast cancers from the three independent 120 
patients. The study protocol was approved by the Ethics Committees of Fukuoka 121 
University Hospital. 122 
 123 
Cell culture and cell proliferation assays 124 
The MCF-7 and MDA-MB-231 human breast cancer cell lines and the LNCaP human 125 
prostate cancer cell line were purchased from the American Type Culture Collection 126 
(Manassas, VA, USA). The KPL-1 human breast cancer cell line was kindly provided 127 
by Dr. Junichi Kurebayashi, Kawasaki Medical School (15). All breast cancer cells 128 
were maintained in DMEM, and LNCaP cells were maintained in RPMI 1640 medium. 129 
All media were supplemented with 10% fetal bovine serum (FBS) and 1% 130 
penicillin/streptomycin. Cell proliferation assays were performed as described 131 
previously (11) with minor modifications. Briefly, cells were seeded in 12-well tissue 132 
culture plates and maintained in complete media with or without 0.1–10 nM Ex-4 or 133 
100 nM exendin (9–39) (Sigma-Aldrich, Saint Louis, MO, USA), and with or without 134 
0.1–10 nM linagliptin (kindly provided by Boehringer Ingelheim Pharma GmbH & Co. 135 
KG, Biberach an der Riss, Germany). Cell proliferation was analyzed after 0–3 days or 136 
48 h after by cell counting using a hemocytometer. 137 
 138 
Construction of GLP-1R-expressing lentiviral vectors and viral transduction 139 
We constructed lentiviral vectors including a Flag epitope tag. A SpeI- and ScaI- treated 140 
pCR-GLP-1R fragment was subcloned into a SpeI- and ScaI-treated pFLAG CMV-2 141 
expression vector (Cat. # E7033 Sigma-Aldrich, Saint Louis, MO, USA). DNA encoding 142 
Flag-GLP-1R was subcloned into XbaI- and NotI–treated pLVSIN-EF1α (Cat. #6186, 143 
Clontech, Mountain View, CA, USA). A lentiviral vector containing Flag-GLP-1R was 144 
generated by transfecting HEK293 cells (Cat. #631152, Clontech). To upregulate 145 
GLP-1R overexpression, we infected MCF-7 cells with pLVSIN-EF1α-Flag GLP-1R at a 146 
multiplicity of infection of 10. Three days after transduction, cells were selected and 147 
cultured with puromycin in DMEM supplemented with 10% bovine serum albumin for 148 
approximately 7 days.  149 
 150 
Animals 151 
Female athymic CAnN.Cg-Foxn1nu/CrlCrlj mice were purchased from Charles River 152 
Laboratories Japan, Inc. and housed in specific-pathogen-free barrier facilities at 153 
Fukuoka University. Mice were treated with either saline (control, n = 10) or 300 154 
pmol/kg body weight/day Ex-4 (Sigma-Aldrich, Tokyo, Japan) (n = 10) through a 155 
mini-osmotic pump (ALZEST, model 1004; DURECT, Cupertino, CA, USA) for 9 156 
weeks. A second group of mice were treated with saline (n = 5), 300 pmol/kg body 157 
weight/day Ex-4 (n = 5), 3nmol/kg body weight/day exendin (9–39) at (n = 5), or 158 
combined Ex-4 and exendin (9–39) (n = 5) through a mini-osmotic pump for 6 weeks. 159 
When the mice reached 6 weeks of age, 1 × 106 or 2 × 106 MCF-7 cells (passage 4–8) 160 
were mixed with 250 μl Matrigel (Becton Dickinson Labware, Bedford, MA, USA) and 161 
transplanted subcutaneously in the flank region. The osmotic pump was transplanted 162 
under the skin of the back of each mouse under local anesthesia, as described previously 163 
(11, 12). When the mice reached 12 or 15 weeks of age, blood samples were collected, 164 
and the mice were euthanized. Tumor volume was calculated with the modified 165 
ellipsoid formula: length × width2 × 0.52, and paraffin-embedded formalin-fixed tumors 166 
were cut into 5-μm sections and prepared for immunofluorescence staining. All 167 
procedures involving animals were reviewed and approved by the institutional Animal 168 
Care subcommittee at Fukuoka University Hospital. 169 
 170 
RT and quantitative real-time PCR 171 
RT and quantitative real-time PCR were performed as described previously (11). Total 172 
mRNA from breast cancer cells was isolated using RNeasy Mini Kits (Qiagen, Venlo, 173 
the Netherlands) and reverse-transcribed into cDNA. PCR reactions were performed 174 
using a Light Cycler 2.0 (Roche, Basel, Switzerland) and SYBR Premix Ex Taq™ II 175 
(Takara, Otsu, Japan). Each sample was analyzed in triplicate and normalized against 176 
TATA-binding protein (TBP) mRNA expression. The primer sequences used were as 177 
follows: human TBP, 5′-TGCTGCGGTAATCATGAGGATA-3′ (forward), 178 
5′-TGAAGTCCAAGAACTTAGCTGGAA-3′ (reverse); human GLP-1R, 179 
5′-GGTTCATCTAGGGACACGTTAGGA-3′ (forward), 180 
5′-GACAGCGTGTGGTCACAGATAAAG-3′ (reverse); aromatase cytochrome P450 181 
(CYP19), 5′-AGCATTTGACCCTTGCTGTGAA-3′ (forward), 182 
5′-AGGCAAGTGGCTGAGGCATAA-3′ (reverse); IL-8, 183 
5′-AGAGCACACAAGCTTCTAGGAC-3′ (forward), 184 
5′-TGGCAAAACTGCACCTTCAC-3′ (reverse); vascular endothelial growth factor 185 
(VEGF), 5′-TTTGGGAACACCGACAAACC-3′ (forward), 186 
5′-ATCCCCAAAGCACAGCAATG-3′ (reverse); cyclooxygenase-2 (COX-2), 187 
5′-ACCGCAAACGCTTTATGCTG-3′ (forward), 188 
5′-TAGAGTGCTTCCAACTCTGCAG-3′ (reverse); Ki67, 5′-TGTGTCGTCGTT 189 
TGTTTGCC-3′ (forward),  190 
5′- TGCGCTCATCCATTCATTCG-3′ (reverse). To verify human GLP-1R mRNA 191 
expression, we also amplified the 890-base pair coding sequence of human GLP-1R 192 
using RT-PCR, as previously reported (11). PCR products were separated by agarose 193 
gel electrophoresis and visualized with ethidium bromide staining. 194 
 195 
Hematoxylin and eosin (HE) staining 196 
The tissue sections were deparaffinized and rehydrated. The sections were stained in 197 
hematoxylin (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 5 min, and washed in 198 
running water for 15 min. Then, the sections were stained with eosin (Muto Pure 199 
Chemicals Co., Ltd.) for 3 min, dehydrated, and mounted by routine methods. 200 
 201 
Immunohistochemistry 202 
Paraffin sections were incubated with anti-GLP-1R (NBP1-97308, Novus Biologicals, 203 
Litteleton, CO, USA), anti-Flag (F1804, Sigma-Aldrich, Saint Louis, MO, USA) or 204 
anti-Ki67 antibody (ab66155; Abcam, Cambridge, UK). Sections analyzed for GLP-1R 205 
and Flag were subsequently incubated with Alexa Fluor 488 goat anti-rabbit IgG 206 
(A-11008, Thermo Fisher Scientific, Rockford, IL, USA), and sections analyzed for 207 
Ki67 were subsequently incubated with Alexa Fluor 546 goat anti-rabbit IgG (A-11010, 208 
Thermo Fisher Scientific, Rockford, IL, USA). Sections were counterstained with 209 
4',6-diamidino-2-phenylindole (DAPI) and visualized with confocal microscopy. 210 
 211 
Bromodeoxyuridine (BrdU) assays 212 
To evaluate cell proliferation in breast cancer cells, the BrdU incorporation assay was 213 
performed using Cell Proliferation ELISA kits (1647229; Roche Applied Science, 214 
Mannheim, Germany). Briefly, three kinds of breast cancer cells were plated at 5000 215 
cells/well in 96-well culture plates in complete media. After attaining 60%–70% 216 
confluence, cells were treated with media containing 10% FBS with or without Ex-4 217 
(0.1–10 nM), and with or without linagliptin (0.1–10nM) for 24 or 48 h. BrdU solution 218 
(10 μM) was added during the last 2 h of stimulation. Next, the cells were dried and 219 
fixed, and the cellular DNA was denatured with FixDenat solution (Roche Applied 220 
Science) for 30 min at room temperature. A peroxidase-conjugated mouse anti-BrdU 221 
monoclonal antibody (Roche Applied Science) was added to the culture plates and the 222 
cells were incubated for 90 min at room temperature. Finally, tetramethylbenzidine 223 
substrate was added and the plates were incubated for 15 min at room temperature, and 224 
the absorbance of the samples was measured using a microplate reader at 450–620 nm. 225 
Mean data are expressed as a ratio to control (non-treated) cell proliferation. 226 
 227 
Apoptosis assays 228 
For labeling nuclei of apoptotic cells, 1.2 × 105 breast cancer cells were plated on glass 229 
coverslips in Lab-Tek Chamber Slides (177380; Nunc, Thermo Scientific, Waltham, 230 
MA, USA) and fixed in 4% paraformaldehyde for 25 min. Terminal deoxynucleotidyl 231 
transferase-mediated dUTP nick end labeling (TUNEL) staining was performed using a 232 
DeadEnd Fluorometric TUNEL System (Promega, Madison, WI, USA) according to the 233 
manufacturer’s protocol. During the final 24 h, cells were incubated with 10 nM Ex-4. 234 
Cells treated with 1 U/100 μl RQ1 RNase-Free DNase (M6101; Promega) for 24 h were 235 
used as a positive control. 236 
 237 
Small interfering (si)RNA knockdown of GLP-1R expression and cell proliferation 238 
assay 239 
To knockdown GLP-1R, we used Stealth RNAi Pre-Designed siRNA (Invitrogen, 240 
Carlsbad, CA, USA), which was designed to target human GLP-1R (HSS104179-81). 241 
Stealth RNAi Negative Control Duplexes (Invitrogen) were used as a negative control. 242 
For transfection, MCF-7 cells were plated at 2 × 105 cells/well in 6-well plates and 243 
transfected with 10 nmol/l of siRNA targeting GLP-1R or negative control siRNA using 244 
MISSION siRNA Transfection Reagent (Sigma-Aldrich). Seventy-two hours after 245 
transfection, cells were subjected to the cell proliferation assay. Briefly, cells were 246 
detached and re-plated in 24-well tissue culture plates in complete media with or 247 
without 10 nM Ex-4. Forty-eight hours after treatment, cells were collected and counted 248 
using a hemocytometer. The siRNA knockdown efficiency was confirmed by RT-PCR 249 
and immunohistochemical analysis of GLP-1R. 250 
 251 
Determination of cAMP concentration 252 
Measurement of cAMP concentration was performed as described previously (11). 253 
Briefly, MCF-7 cells were plated in 96-well plates at 1.5 × 104 cells/well and cultured 254 
overnight. Next, cells were serum-deprived for 24 h and incubated with saline (control) 255 
or 10 nM Ex-4 for 0, 15, 30 or 60 min. After incubation, the medium was aspirated and 256 
lysis buffer was added. Intracellular cAMP concentration ([cAMP]i) was determined 257 
using a cAMP Enzyme Immunoassay Kit (Cyman chemical, Ann Arbor, MI) according 258 
to the manufacturer’s instructions. 259 
 260 
Insulin measurements 261 
Insulin concentrations in mouse serum were measured using an Ultra Sensitive Mouse 262 
Insulin ELISA Kit (Morinaga Institute of Biological Science, Inc. Kanagawa, Japan) 263 
according to the manufacturer’s protocol. 264 
 265 
Detection of NF-κB nuclear translocation 266 
MCF-7 cells were plated at 3 × 105 cells/plate in 60-mm culture plates in complete 267 
media. After attaining 60%–70% confluence, cells were treated with media containing 268 
10% FBS with or without 10 nM Ex-4 for 0, 15, 30 or 60 min. The nuclear protein 269 
extracts were isolated from MCF-7 cells using a Nuclear Extraction Kit (NBP2-29447, 270 
Novus). NF-κB p65 content was determined using an ELISA kit (NBP2-31042, Novus). 271 
These procedures were performed according to the manufacturer’s instructions. To 272 
evaluate GLP-1R inhibition of NF-κB p65 in breast cells, MCF-7 cells were pretreated 273 
for 30 min with or without 100 nM exendin (9–39), then treated with or without 10 nM 274 
Ex-4 for 15 min. After treatment, nuclear extraction and measurement of NF-κB p65 275 
were performed as described above. 276 
 277 
IL-8, VEGF and COX-2 measurements 278 
MCF-7 cells were plated at 1 × 105 cells/well in 6-well culture plates in complete media. 279 
After attaining 60%–70% confluence, cells were treated with media containing 10% 280 
FBS with saline (control) or 10 nM Ex-4 for 72 h. Seventy-two hours after treatment, 281 
media were collected, and IL-8, VEGF and COX-2 concentrations in the media were 282 
measured using the following ELISA kits: Human CXCL8/IL-8 Quantikine ELISA Kit 283 
(R&D Systems, MN, USA), Human VEGF Quantikine ELISA Kit (R&D Systems) and 284 
Human COX-2 ELISA Kit (RayBiotech, GA, USA). 285 
 286 
Plasmids, transient transfections and luciferase assays 287 
To evaluate NF-κB activation, luciferase reporter assays were performed in MCF-7 288 
cells transiently transfected with pGL3-MMTV or pNF-κB-LUC reporter constructs, as 289 
described previously (16). Briefly, MCF-7 cells were transfected with 0.5 µg of reporter 290 
DNA using FuGENE HD Transfection Reagent (Roche). Next, cells were maintained in 291 
media containing 10% FBS with saline (control) or 10 nM Ex-4 for 24 h. Luciferase 292 
activity was assayed using the Dual-Luciferase Reporter Assay (Promega). Transfection 293 
efficiency was normalized to Renilla luciferase activity generated by co-transfection of 294 
cells with 10 ng/well pRL-SV40 (Promega). 295 
 296 
Western blot analysis 297 
Western blotting was performed as described previously (17). The following primary 298 
antibodies were used: anti-phospho-Akt (Thr-308) (#2965; Cell Signaling), anti-Akt 299 
(#9272; Cell Signaling), anti-phospho-nuclear factor of kappa light polypeptide gene 300 
enhancer in B-cells inhibitor α (IκBα) (Ser32/36) (#9246; Cell Signaling) and anti-IκBα 301 
(#4814; Cell Signaling). Protein expression was examined in MCF-7 cells that were 302 
incubated in media containing 10% FBS and stimulated with or without 10 nM Ex-4 for 303 
0, 5, 10, 15, 30 or 60 min. 304 
 305 
Statistical analysis 306 
Unpaired t-tests, one-way ANOVA and two-way ANOVA for repeated measures were 307 
performed for statistical analysis as appropriate. P-values less than 0.05 were 308 
considered statistically significant. Results are expressed as mean ± SEM. 309 
 310 
RESULTS 311 
GLP-1R is expressed in human breast cancer 312 
To examine whether GLP-1R is expressed human breast cancer tissue, we first 313 
conducted immunohistochemical analysis of breast cancers obtained from non-diabetic 314 
patients. As depicted Figure 1A, typical ductal structure was observed by HE staining. 315 
Immunohistochemical staining for GLP-1R revealed obvious membrane-localized 316 
GLP-1R expression in human breast cancer tissue (Figure 1A). GLP-1R staining 317 
representative of that observed in breast cancer tissues from three independent patients 318 
is depicted in Figure 1A. To further examine GLP-1R expression in human breast 319 
cancer cell lines, we performed immunohistochemical staining for GLP-1R in three 320 
breast cancer cell lines: MCF-7, which exhibits highly estrogen-sensitive proliferation; 321 
MDA-MB-231, which exhibits estrogen-independent proliferation; and KPL-1, which 322 
exhibits low sensitivity to estrogen. As shown in Figure 1B, GLP-1R was abundantly 323 
expressed in the breast cancer cell lines as well as in LNCaP prostate cancer cells, in 324 
which we have previously detected GLP-1R expression (11). When we counted 325 
GLP-1R-positive cells and corrected for DAPI-positive cells, GLP-1R expression levels 326 
in MCF-7 and KPL-1 cells were not as high as those in LNCaP cells. However, GLP-1R 327 
was highly expressed in MDA-MB-231 cells, at a level comparable to that in LNCaP 328 
cells. On the basis of our previous report (11), we next performed RT-PCR on the 329 
890-base pair coding sequence of GLP-1R to confirm expression of the GLP-1R gene. 330 
GLP-1R mRNA was abundantly expressed in MCF-7 cells, but expression levels were 331 
lower in MDA-MA-231 and KPL-1 cells (Fig. 1C). The sequence of the PCR product 332 
was compatible with that of human GLP-1R cDNA as tested by direct sequencing (data 333 
not shown). Quantitative real-time RT-PCR analysis revealed that GLP-1R expression 334 
levels were significantly lower in breast cancer cell lines than in LNCaP cells. Among 335 
the three breast cancer cell lines, the highest GLP-1R gene expression level was 336 
detected in MCF-7 cells (Fig. 1D). To confirm that GLP-1R expression is exclusively 337 
localized to the breast cancer cell membrane, and not to the cytosol or nucleus, we 338 
constructed a GLP-1R-expressing lentiviral vector containing a Flag epitope tag and 339 
transfected it into MCF-7 cells. Whereas immunohistochemical staining of GLP-1R 340 
revealed a small amount of immunofluorescence that was not located in the membrane 341 
fraction, probably because of limited antibody specificity, immunohistochemical 342 
staining of Flag was completely localized to the membrane (Figure 1E). These data 343 
suggest that GLP-1R is expressed in the breast cancer cell membrane in both human 344 
breast cancer tissue and cell lines. 345 
 346 
Ex-4 attenuated breast cancer cell proliferation but did not induce apoptosis 347 
We next examined the effect of Ex-4 on breast cancer cell number using a growth curve. 348 
Treatment with 0.1–10 nM Ex-4 significantly decreased the number of MCF-7, 349 
MDA-MB-231 and KPL-1 cells in a dose-dependent manner (Fig. 2A–C). We next 350 
examined the mechanism through which Ex-4 decreased the number of breast cancer 351 
cells. First, we performed BrdU incorporation assays to assess DNA synthesis. Ex-4 352 
treatment for 24 h significantly decreased DNA synthesis in all three breast cancer cell 353 
lines in a dose-dependent manner (Fig. 2D–F). However, treatment with 10 nM Ex-4, 354 
the highest Ex-4 dose used in our experiments, did not induce TUNEL-positive 355 
apoptotic cells. In contrast, TUNEL-positive cells were observed following DNase 356 
treatment as a positive control in MCF-7 cells (Fig. 2G). The same results were also 357 
observed in MDA-MB-231 and KPL-1 cells (data not shown). These data suggest that 358 
Ex-4 attenuates breast cancer cell proliferation but does not induce apoptosis. To further 359 
examine the anti-breast cancer effect of incretin therapy, we investigated the effect of a 360 
DPP-4 inhibitor, linagliptin, on breast cancer cell proliferation. However, linagliptin had 361 
no effect on breast cancer cell proliferation (Figure H, I). 362 
 363 
Ex-4 attenuates breast cancer cell proliferation through GLP-1R activation 364 
Because the most abundant GLP-1R gene expression was observed in MCF-7 cells, we 365 
used this cell line for subsequent experiments. The anti-proliferative effect of Ex-4 was 366 
completely reversed by the GLP-1R antagonist exendin (9–39) (Fig. 3A). Additionally, 367 
GLP-1R knockdown using siRNA abolished the reduction in MCF-7 cell number by 368 
Ex-4 (Fig. 3B), suggesting that the reduction in breast cancer cell number by Ex-4 369 
occurred through GLP-1R activation. To confirm the substantial reduction of GLP-1R 370 
by the siRNA targeting GLP-1R (siGLP-1R), we conducted RT-PCR of the 890-base 371 
pair GLP-1R open reading frame and immunohistochemistry. As shown in Figure 3 C 372 
and D, GLP-1R was specifically and completely knocked down by siGLP-1R. Because 373 
breast cancer cell proliferation partially depends on aromatase activity and elevated 374 
estrogen production by adipose tissue, we next examined whether the anti-proliferative 375 
effects of Ex-4 were caused by decreased aromatase action in MCF-7 cells. Surprisingly, 376 
as shown in Figure 3E, Ex-4 treatment significantly stimulated expression of the 377 
aromatase gene CYP19. Downstream of the GLP-1R canonical pathway, cAMP and 378 
PKA activation occur. In MCF-7 cells, Ex-4 increased intracellular cAMP 379 
concentrations rapidly and significantly compared with control (Figure 3F). These data 380 
suggest that GLP-1R is functionally intact in MCF-7 cells, and Ex-4 attenuates breast 381 
cancer cell proliferation through GLP-1R activation, regardless of aromatase activity. 382 
 383 
Ex-4 attenuates breast cancer growth in vivo. 384 
To examine the anti-breast cancer effect of Ex-4 in vivo, we transplanted MCF-7 cells 385 
into athymic nude mice. Nine weeks after subcutaneous transplantation of MCF-7 cells 386 
into the flank region of mice, tumor formation was observed, and tumor size was found 387 
to be decreased in Ex-4-treated mice (Fig. 4A). Calculation of tumor size using the 388 
modified ellipsoid formula revealed that Ex-4 significantly decreased tumor size to 389 
almost half that of the control (Fig. 4B). As shown in Figure 4C and D, body weight and 390 
blood glucose levels were not changed following Ex-4 treatment. Compared with 391 
control, serum insulin levels were modestly increased in Ex-4-treated mice (control: 392 
0.36 ± 0.05 ng/mL vs. Ex-4: 0.44 ± 0.07 ng/mL), although this effect was not 393 
statistically significant (P = 0.18) (Fig. 4E). Immunohistochemical analysis of 394 
paraffin-embedded sections of subcutaneous breast cancer tumors demonstrated that 395 
Ki67, a marker of cell proliferation and cell cycle progression, was clearly localized to 396 
the nucleus. Furthermore, Ki67 expression was dramatically and significantly decreased 397 
by Ex-4 treatment (Fig. 4F). To further demonstrate that Ex-4 attenuates breast cancer 398 
growth via activation of GLP-1R in vivo, we treated mice with Ex-4 and with or without 399 
exendin (9–39), a GLP-1R antagonist. As shown in Figure 4G, the reduction in Ki67 400 
mRNA expression was significantly enhanced by combined treatment with Ex-4 and 401 
exendin (9–39), with expression levels reduced to control levels. These data suggest that 402 
Ex-4 attenuates breast cancer growth through inhibition of cell proliferation in vivo. 403 
Additionally, immunohistochemical staining of Ki67 and counting of Ki67-positive 404 
cells in mouse subcutaneous breast cancer tumors revealed that the Ex-4-induced 405 
decrease in Ki67-positive cell number was significantly canceled by combined 406 
treatment with Ex-4 and exendin (9–39) (Fig. 4H). These data suggest that Ex-4 407 
attenuates breast cancer growth via GLP-1R activation in vivo, independent of its effects 408 
on glucose metabolism.  409 
 410 
Ex-4 inhibits NF-κB activation in breast cancer cells 411 
Finally, we examined the molecular mechanism through which Ex-4 attenuates breast 412 
cancer cell proliferation. NF-κB is constitutively activated in cancers, including breast 413 
cancer, and contributes to cancer cell survival and cancer development (18). Therefore, 414 
we examined whether Ex-4 attenuates NF-κB activation in MCF-7 cells. As shown in 415 
Figure 5A, Ex-4 significantly inhibited NF-κB (p65) translocation into the nucleus 416 
during the early phase of Ex-4 treatment. The inhibitory effect of Ex-4 on NF-κB 417 
activation was completely abolished by the GLP-1R antagonist exendin (9–39) (Fig. 418 
5B), suggesting that inhibition of NF-κB nuclear translocation and transactivation were 419 
induced by GLP-1R activation. Furthermore, in a luciferase assay using the NF-κB 420 
response element, 24-h incubation increased NF-κB transactivation in both saline 421 
(control) and Ex-4-treated cells; however, the extent of transactivation was significantly 422 
lower in Ex-4-treated cells than in control cells, suggesting that transactivation of the 423 
promoter containing the NF-κB binding site was inhibited by Ex-4 (Fig. 5C). We next 424 
investigated gene expression of NF-κB target genes in breast cancer cells treated with 425 
Ex-4. IL-8, VEGF and COX-2 are target genes of NF-κB in breast cancer. These genes 426 
play important roles in processes involved in breast cancer development, such as 427 
inflammation and angiogenesis (18). As shown in Fig. 5D, whereas IL-8 gene 428 
expression was dramatically increased in saline-treated control cells, Ex-4 treatment 429 
significantly inhibited gene expression. Additionally, VEGF and COX-2 mRNA 430 
expression were also significantly attenuated by Ex-4 treatment, compared with control 431 
(Fig. 5E, F). To confirm the reduction of target gene expression by Ex-4 treatment, we 432 
next performed ELISA assays using conditioned media from MCF-7 cells treated with 433 
or without Ex-4 to assess protein levels. As shown in Figures 5G and H, both IL-8 and 434 
VEGF production by MCF-7 cells were significantly decreased by Ex-4 treatment. 435 
Unfortunately, COX-2 protein expression levels were too low to be detected by ELISA 436 
(data not shown). Because transactivation and nuclear translocation of NF-κB are 437 
regulated by IκBα phosphorylation, we next performed western blotting to examine 438 
IκBα phosphorylation. As depicted in Figure 5I, Ex-4 reduced phosphorylated IκBα 439 
levels after 15 min treatment. Furthermore, Akt, a kinase that phosphorylates IκBα and 440 
transactivates NF-κB, was dephosphorylated and inactivated by Ex-4 treatment in 441 
MCF-7 cells over the same time course as IκBα dephosphorylation (Fig. 5J). These data 442 
suggest that Ex-4 could attenuate breast cancer cell proliferation through inhibition of 443 
NF-κB activation and subsequent reduction of target gene expression. 444 
 445 
DISCUSSION 446 
In the present study, we demonstrated that GLP-1R was expressed in human breast 447 
cancer tissue and cell lines and that the GLP-1R agonist Ex-4 attenuated breast cancer 448 
growth by inhibiting NF-κB activation both in vivo and in vitro. Recently, incretin 449 
therapies, which include GLP-1R agonists and dipeptidyl peptidase-4 inhibitors, have 450 
become popular anti-diabetic treatments throughout the world (19), including in Japan 451 
(20). There are many benefits of incretin therapy, such as pancreatic b-cell preservation, 452 
lower risk of weight gain and fewer hypoglycemic attacks (21). Additionally, incretin 453 
treatment is a therapeutic option for T2DM even during end-stage renal disease (22). 454 
Furthermore, incretin therapies are expected to have tissue-protective effects beyond 455 
those associated with their glucose-lowering capacity (1). However, the current 456 
considerable interest in incretin therapies has raised the issue of their long-term safety, 457 
including the risk of carcinogenesis. 458 
 GLP-1 action in cancer is controversial, as we discussed in a previous review 459 
(13). Continuous exposure to liraglutide, a GLP-1R agonist, was associated with a 460 
marked increase in plasma calcitonin levels and thyroid C-cell hyperplasia in wild-type 461 
mice but not in GLP-1R-deficient mice (23). Furthermore, GLP-1R expression has been 462 
detected in human neoplastic hyperplastic lesions of thyroid C cells (24). Thus, it can be 463 
speculated that these reports warn of a risk of carcinogenesis associated with incretin 464 
therapies. In contrast, another study demonstrated an anti-colon cancer effect of the 465 
GLP-1R agonist Ex-4 (25), similar to that demonstrated in our study. Specifically, Ex-4 466 
was shown to increase intracellular cAMP levels and inhibit glycogen synthase kinase 3 467 
and ERK-MAPK activation, which led to decreased colony formation and augmented 468 
apoptosis induced by irinotecan, a topoisomerase I inhibitor, in CT26 murine colon 469 
cancer cells (25). Additionally, our previous two studies demonstrated an anti-prostate 470 
cancer effect of the GLP-1R agonist Ex-4 by inhibition of ERK-MAPK activation both 471 
in vivo and in vitro using a similar procedure to the present study (11). Furthermore, we 472 
demonstrated an additional reduction in prostate cancer growth by combined Ex-4 and 473 
metformin therapy (12). Interestingly, our findings are supported by the results of a 474 
recent large-scale clinical trial (26), the LEADER trial, which used the GLP-1R agonist 475 
liraglutide. The primary endpoint of this trial was a reduction in cardiovascular events. 476 
However, in the supplemental appendix, it was reported that the GLP-1R agonist 477 
liraglutide significantly decreased prostate cancer compared with the placebo group 478 
with a hazard ratio of 0.54. Furthermore, no cancer incidences were significantly 479 
increased by liraglutide (26). These data suggest that GLP-1 action might inhibit 480 
prostate cancer, and that no cancers are initiated or accelerated by GLP-1 action. 481 
Although we clearly detected membrane localized GLP-1R expression in human breast 482 
cancer tissue and cell lines (Fig. 1), the GLP-1R agonist liraglutide did not reduce breast 483 
cancer risk in the LEADER trial (26). In the present study, we recruited non-diabetic 484 
patients with breast cancer; however, in contrast, the LEADER trial enrolled patients 485 
with T2DM. Therefore, some differences in findings might be related to the different 486 
disease background in patients. Further elucidation regarding the anti-breast cancer 487 
effect of GLP-1R agonist is required. 488 
In the present study, Ex-4 inhibited NF-κB activation in breast cancer cells. 489 
NF-κB is one of the most important transcription factors not only in inflammatory 490 
diseases, but also in metabolic diseases, such as T2DM (27). Recently, T2DM has been 491 
recognized as an inflammatory disease whose pathological characteristics include 492 
macrophage and T-cell infiltration into adipose tissue (28). Accordingly, inhibition and 493 
knockdown of inflammatory chemokines resulted in a reduction in blood glucose levels, 494 
as we previously reported using a knockout mouse model lacking the chemokine-like 495 
protein osteopontin (29). Furthermore, it has been reported that inhibition of NF-κB 496 
activation resulted in glucose-lowering effects. Salsalate, a non-steroidal 497 
anti-inflammatory drug, has been reported to improve both insulin sensitivity (30) and 498 
insulin secretion (31), and glucose tolerance was subsequently improved. Additionally, 499 
chronic activation of NF-κB by overexpression of IκB kinase-b in liver resulted in 500 
systematic insulin resistance (32). Furthermore, NF-κB is one of the key regulators of 501 
diabetic vascular complications (33). Indeed, previous reports have revealed inhibition 502 
of NF-κB activation by the GLP-1 and GLP-1R agonists liraglutide and Ex-4 in cell and 503 
animal models, including a cognitive dysfunction model (34), a cardiac fibrosis model 504 
(35), a pulmonary fibrosis model (36), the pancreatic b-cell MIN6 line (37), endothelial 505 
cells (38) and vascular smooth muscle cells (39). In our previous study, we also 506 
demonstrated that Ex-4 inhibited NF-κB nuclear translocation in macrophages; this was 507 
one of the molecular mechanisms by which the GLP-1R agonist reduced atheroma 508 
formation in apoE-deficient mice (4). In the present study, we demonstrated inhibition 509 
of NF-κB transactivation and reduction of target gene expression by a GLP-1R agonist 510 
(Fig. 5). In addition to metabolic diseases, NF-κB is also a key regulator of cancer 511 
biology (40). Taken together, these findings suggest that NF-κB inhibition by GLP-1R 512 
agonists might be effective not only against metabolic disease, but also against cancer 513 
development. 514 
 Including our previous study (11, 12), the exclusive membrane localization of 515 
GLP-1R has not been confirmed by immunohistochemistry in previously performed 516 
experiments, because the antibody to GLP-1R lacks sufficient sensitivity for this 517 
methodology. In the present study we confirmed the membrane localization of GLP-1R 518 
using a lentiviral vector containing a Flag epitope (Fig. 1E). This system revealed that 519 
Ex-4 acted through GLP-1R that was exclusively located in the cell membrane. 520 
Furthermore, this system might be useful for overexpression experiments of GLP-1R in 521 
future studies. In both in vivo (Fig. 3A) and in vitro (Fig. 4G, H) experiments, the 522 
anti-proliferative effect of Ex-4 on breast cancer was inhibited by the GLP-1R 523 
antagonist exendin (9-39) or by knocking down GLP-1R (Fig. 3B). These data suggest 524 
that the anti-breast cancer effect of Ex-4 is mediated directly by activating GLP-1R 525 
expressed in breast cancer cell membranes. Unfortunately, the DPP-4 inhibitor 526 
linagliptin did not attenuate breast cancer cell proliferation, probably because GLP-1R 527 
activation was lower than when a GLP-1R agonist was used. However, a retrospective 528 
cohort study reported that DPP-4 inhibitors might reduce breast cancer risk in 529 
Taiwanese women with T2DM (41). Therefore, the anti-breast cancer effect of DPP-4 530 
inhibitors requires further elucidation. 531 
Prior to our present study, two studies from other groups suggested anti-breast 532 
cancer effects of the GLP-1R agonist Ex-4 (42, 43). Similar to our present study, both 533 
studies used MCF-7 cells. In contrast to our study, however, they observed apoptosis in 534 
MCF-7 cells, whereas we did not. The discrepancy between our results and these 535 
previous reports might be explained by different Ex-4 doses. Previous reports treated 536 
MCF-7 cells with a much higher dose of Ex-4 (in the order of micromoles) than our 537 
study (in the order of nanomoles). We chose this dose on the basis of our previous study 538 
in prostate cancer cells (11). Furthermore, data from studies in humans indicate that the 539 
dose of Ex-4 that we used in vivo and in vitro is comparable to clinical pharmacological 540 
doses (44). 541 
In conclusion, we detected GLP-1R expression in human breast cancer tissue and 542 
cell lines and demonstrated that Ex-4, a GLP-1R agonist, attenuated breast cancer by 543 
inhibiting NF-κB activation and target gene expression. 544 
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 710 
Figure legends 711 
FIG. 1. Glucagon-like peptide-1 receptor (GLP-1R) expression in breast cancer 712 
(A) Hematoxylin and eosin (HE) staining and immunohistochemistry were performed to 713 
examine GLP-1R expression in human breast cancer tissues obtained by mammary 714 
gland resection. Staining presented is representative of that observed in breast cancer 715 
tissues from three independent non-diabetic patients. Sections were stained with HE or 716 
anti-GLP-1R antibody and counterstained with 4',6-diamidino-2-phenylindole (DAPI; 717 
magnification, 400×). (B) Immunohistochemistry was performed to examine GLP-1R 718 
expression in breast cancer cell lines. All samples were counterstained with DAPI 719 
(magnification, 400×). GLP-1R-positive cells were counted and normalized against 720 
DAPI staining in four individual fields of view. Unpaired t-tests were performed to 721 
calculate statistical significance (*P < 0.05 vs. LNCaP prostate cancer cell line; **P < 722 
0.01 vs. LNCaP; ##P < 0.01 vs. MDA-MB-231 breast cancer cell line) (n = 3). (C) 723 
RT-PCR was performed to examine mRNA levels of the 890-base pair GLP-1R open 724 
reading frame. TATA-binding protein mRNA (TBP) was used as an input control. (D) 725 
Quantitative RT-PCR was performed using a set of primers targeting exon 13 of 726 
GLP-1R. TBP expression was used for normalization. Unpaired t-tests were performed 727 
to calculate statistical significance (**P < 0.01 vs. LNCaP; #P < 0.05 vs. MCF-7) (n = 3). 728 
(E) A lentiviral vector containing Flag-GLP-1R was transfected into MCF-7 cells. 729 
Transfected MCF-7 cells were subjected to immunohistochemical staining of GLP-1R 730 
and Flag, and counterstaining with DAPI (magnification, 400×). 731 
 732 
FIG. 2. Exendin-4 (Ex-4) attenuated breast cancer cell proliferation but did not 733 
induce apoptosis 734 
(A) MCF-7, (B) MDA-MB-231 and (C) KPL-1 breast cancer cell lines were maintained 735 
in media supplemented with 10% fetal bovine serum (FBS) with saline or Ex-4 (0.1–10 736 
nM). After 0, 24, 48 and 72 h, the cells were harvested and cell proliferation was 737 
analyzed by cell counting using a hemocytometer. Black circles with solid line, control 738 
(non-treated; saline); black squares with dotted line, Ex-4 (0.1 nM); white circles with 739 
solid line, Ex-4 (1 nM); white squares with dotted line, Ex-4 (10 nM). Unpaired t-tests 740 
were performed to calculate statistical significance (*P < 0.05 vs. control; **P < 0.01 vs. 741 
control) (n = 3). (D) MCF-7, (E) MDA-MB-231 and (F) KPL-1 cells were plated at 742 
5000 cells/well in 96-well plates in media supplemented with 10% FBS, and incubated 743 
with Ex-4 (0–10 nM) for 24 h. Bromodeoxyuridine (BrdU) solution was added during 744 
the last 4 h, and cells were harvested for measurement of DNA synthesis using a 745 
microplate reader to measure absorbance at 450–620 nm. Mean data are expressed as a 746 
ratio of control cell proliferation. Unpaired t-tests were performed to calculate statistical 747 
significance (*P < 0.05 vs. control; **P < 0.01 vs. control) (n = 3). (G) MCF-7 cells were 748 
plated on glass coverslips in 6-well plates. After incubation with 10 nM Ex-4 or 1 749 
U/100 µl RQ1 DNase for 24 h, apoptotic cells were detected with terminal 750 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Images shown 751 
are representative of triplicate independent experiments. (H) MCF-7 cells were 752 
maintained in media supplemented with 10% FBS containing dimethyl sulfoxide 753 
(control) or linagliptin (0.1–10 nM). After 48 h, the cells were harvested, and cell 754 
proliferation was analyzed by cell counting using a hemocytometer. Unpaired t-tests 755 
were performed to calculate statistical significance (**P < 0.01 vs. 0 h) (n = 3). (I) 756 
MCF-7 cells were plated at a density of 5000 cells/well in 96-well plates in media 757 
supplemented with 10% FBS, and incubated with linagliptin (0.1–10 nM) for 48 h. 758 
BrdU solution was added during the last 4 h, and cells were harvested for measurement 759 
of DNA synthesis using a microplate reader at 450–620 nm. Mean data are expressed as 760 
a ratio of control (non-treated) cell proliferation. Unpaired t-tests were performed to 761 
calculate statistical significance (n = 3). 762 
 763 
FIG. 3. Exendin-4 (Ex-4) attenuated breast cancer cell proliferation through 764 
glucagon-like peptide-1 receptor (GLP-1R) activation 765 
(A) MCF-7 cells were maintained in media supplemented with 10% fetal bovine serum 766 
(FBS) with or without 10 nM Ex-4 or 100 nM exendin (9–39). After 0, 24, 48 and 72 h, 767 
the cells were harvested, and cell proliferation was analyzed by cell counting using a 768 
hemocytometer. Black circles with solid line, control (non-treated); black squares with 769 
dotted line, Ex-4 (10 nM); white circles with solid line, exendin (9–39) (100 nM); white 770 
squares with dotted line, Ex-4 (10 nM) + exendin (9–39) (100 nM). Unpaired t-tests 771 
were performed to calculate statistical significance (*P < 0.05 vs. control; **P < 0.01 vs. 772 
control) (n = 3). (B) MCF-7 cells were transfected with either negative control duplexes 773 
or small interfering (si)RNA targeting GLP-1R and maintained in media with 10% FBS 774 
with saline or 10 nM Ex-4. After 0 or 72 h, the cells were harvested, and cell 775 
proliferation was analyzed by cell counting using a hemocytometer. Unpaired t-tests 776 
were performed to calculate statistical significance (**P < 0.01 vs. control without Ex-4) 777 
(n = 3). (C) RT-PCR of the 890-base pair GLP-1R open reading frame and (D) 778 
immunohistochemical staining of GLP-1R were performed after transfection of MCF-7 779 
cells with vector containing a control siRNA (si control) or an siRNA targeting GLP-1R 780 
(si GLP-1R). (C) RT-PCR for TATA-binding protein mRNA (TBP) was performed as 781 
an internal control. (D) Transfected cells were counterstained with 782 
4',6-diamidino-2-phenylindole (DAPI; magnification, 400×). (E) MCF-7 cells 783 
maintained in DMEM without phenol red supplemented with 10% charcoal-filtered 784 
FBS in 6-well plates were stimulated with 10 nM Ex-4 or saline (control) for 24 h. RNA 785 
was isolated and quantitative RT-PCR was performed to examine aromatase 786 
cytochrome P450 (CYP19) mRNA expression. TBP expression was used for 787 
normalization. Unpaired t-tests were performed to calculate statistical significance (*P < 788 
0.05 vs. control) (n = 3). (F) Intracellular cAMP concentrations were measured at 0, 15, 789 
30 and 60 min after saline (control; white bar) or 10 nM Ex-4 (black bar) stimulation. 790 
Data are expressed as relative induction compared with 0 min. Unpaired t-tests were 791 
performed to calculate statistical significance (**P < 0.01 vs. control, ##P < 0.01 vs. 0 792 
min.) (n = 3). 793 
 794 
FIG. 4. Exendin-4 (Ex-4) attenuated breast cancer growth in vivo. 795 
(A) Athymic CAnN.Cg-Foxn1nu/CrlCrlj mice (6 weeks of age) were transplanted with 796 
1 ´ 106 MCF-7 cells (passages 4–8) and treated with either saline (control; n = 10) or 797 
Ex-4 (300 pmol/kg body weight/day; n = 10). Tumors were imaged when the mice 798 
reached 15 weeks of age. (B) Tumor volume was calculated with the modified ellipsoid 799 
formula. Unpaired t-tests were performed to calculate statistical significance (**P < 0.01 800 
vs. control). Characteristics of Ex-4-treated athymic mice following transplantation of 801 
MCF cells: (C) body weight (g), (D) plasma glucose (mg/dL) and (E) plasma insulin 802 
(ng/mL). Black circles with solid line, control (saline); black squares with dotted line, 803 
Ex-4. Two-way ANOVA for repeated measures (C and D), and unpaired t-tests (E) 804 
were performed to calculate statistical significance. (F) Sections (5 µm) were subjected 805 
to immunohistochemistry for Ki67 and counterstained with 806 
4',6-diamidino-2-phenylindole (DAPI; magnification, 400×). Ki67-positive cells were 807 
quantified by analyzing the fraction of stained cells in the tumor relative to the total 808 
number of nuclei. Values are expressed as a percentage of positive cells. Unpaired 809 
t-tests were performed to calculate statistical significance (**P < 0.01 vs. control). 810 
Athymic CAnN.Cg-Foxn1nu/CrlCrlj female mice were treated with either saline 811 
(control, n = 5), Ex-4 (300 pmol/kg body weight/day, n = 5), exendin (9–39) (3 nmol/kg 812 
body weight/day, n = 5) or combined Ex-4 and exendin (9–39) (n = 5). When the mice 813 
reached 6 weeks of age, 2 × 106 MCF-7 cells (passage 4–8) were transplanted 814 
subcutaneously into the flank region. An osmotic pump was transplanted under the skin 815 
of the back of each mouse under local anesthesia. At 12 weeks of age, mice were 816 
euthanized, and tumors were removed. (G) After isolation of RNA from homogenized 817 
tumor tissue, RT and quantitative real-time PCR were performed to detect the 818 
expression of Ki67 mRNA in the tumors. One-way ANOVA were performed to 819 
calculate statistical significance (*P < 0.05 vs. control, #P < 0.05 vs. Ex-4). (H) Sections 820 
(5 μm) were subjected to immunohistochemical staining for Ki67 and counterstained 821 
with DAPI (magnification, 400×). Ki67-positive cells were quantified by analyzing the 822 
fraction of stained cells in the tumor relative to the total number of nuclei. Values are 823 
expressed as a percentage of positive cells (**P < 0.01 vs. control, ##P < 0.01 vs. Ex-4). 824 
 825 
FIG. 5. Exendin-4 (Ex-4) inhibits nuclear factor (NF)-κB (p65) translocation into 826 
the nucleus and its transcriptional activity via glucagon-like peptide-1 receptor 827 
(GLP-1R) 828 
(A) MCF-7 cells were treated with saline (control) or 10 nM Ex-4 diluted in media 829 
containing 10% fetal bovine serum (FBS) for 0, 15, 30 and 60 min. Nuclear protein 830 
extracts were then isolated from MCF-7 cells. NF-κB p65 levels were determined by 831 
ELISA. (*P < 0.05 vs. control [nucleus]) (n = 3). (B) MCF-7 cells were treated with or 832 
without 10 nM Ex-4 for 15 min and pretreated for 30 min with or without 100 nM 833 
exendin (9–39). Nuclear extraction and NF-κB p65 measurement were then performed 834 
as described above. Unpaired t-tests were performed to calculate statistical significance 835 
(*P < 0.05 vs. control [nucleus]) (n = 3). (C) MCF-7 cells were transiently transfected 836 
with pGL3-TK-NF-κB and maintained in media containing 10% FBS with saline 837 
(control, white bar, n = 3) or 10 nM Ex-4 (black bar, n = 3) for 24 h. Luciferase activity 838 
was then measured. Transfection efficiency was adjusted by normalizing firefly 839 
luciferase activity to Renilla luciferase activity. Unpaired t-tests were performed to 840 
calculate statistical significance (*P < 0.05 vs. control, ##P < 0.01 vs. 0 h). MCF-7 cells 841 
were treated with saline (control, white bar, n = 3) or 10 nM Ex-4 (black bar, n = 3) 842 
diluted in media containing 10% FBS for 0, 3, 6, 12 and 24 h. RNA was isolated and 843 
quantitative RT-PCR was performed to examine the expression of (D) IL-8, (E) vascular 844 
endothelial growth factor (VEGF) and (F) cyclooxygenase-2 (COX-2) mRNA. Unpaired 845 
t-tests were performed to calculate statistical significance (*P < 0.05, **P < 0.01 vs. 846 
control, #P < 0.05, ##P < 0.01 vs. 0 h). (G) IL-8 and (H) VEGF protein levels secreted 847 
into the culture medium were assayed by ELISA. Unpaired t-tests were performed to 848 
calculate statistical significance (*P < 0.05 vs. control) (n = 3). MCF-7 cells maintained 849 
in media containing 10% FBS were stimulated with 10 nM Ex-4 or saline (control) for 0, 850 
5, 10, 15, 30 and 60 min. Cell lysates were harvested and subjected to western blotting 851 
to assess (I) phosphorylated Akt (Thr-308)/Akt and (J) phosphorylated IκBα/IκBα 852 
expression. 853 
 854 
 855 
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revised MSs)
Phospho-Akt (Thr308) Phospho-Akt (Thr308) (C31E5E) Rabbit mAb Cell Signaling Technology, #2965 Rabbit; monoclonal 1/1000 AB_2255933
Akt Akt antibody Cell Signaling Technology, #9272 Rabbit; polyclonal 1/1000 AB_329827
Phospho-IκBα (Ser32/36) Phospho-IκBα (Ser32/36)(5A5) Mouse mAb Cell Signaling Technology, #9246 Mouse; monoclonal 1/1000 AB_2151442
IκBα IκBα(L35A5) Mouse mAb(Amino-terminal Antigen) Cell Signaling Technology, #4814 Mouse; monoclonal 1/1000 AB_390781
Glyceraldehyde 3-phosphate dehydrogenase GAPDH(V-18) Santa Cruz, sc-20357 Rabbit; polyclonal 1/500 AB_641107
GLP1R GLP1R antibody Novus Biologicals, NBP1-97308 Rabbit; polyclonal 1/100 AB_11139100
Ki67 Ki67 antibody Abcam, ab66155 Rabbit; polyclonal 1/200 AB_1140752
 	
 Sigma-Aldrich, F1804 Mouse; monoclonal 1/1000 AB_262044
